Navigation Links
Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging,Growth Opportunities Conference

BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- Alfacell Corporation today announced that Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of the company's product development programs at 8 a.m. EDT on Thursday, July 12, 2007, at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference in New York.

The audio and slide presentation will be available live at http://www.wsw.com/webcast/ceut6/acel.ob/. A replay will be available at this address within 24 hours of the presentation and will be archived for 90 days.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE(R), is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product,
'"/>




Page: 1 2

Related medicine technology :

1. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
2. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
3. Researchers Identify Intracellular Pathway of Alfacells Onconase
4. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
5. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
6. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
7. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
8. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
9. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
10. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
11. The Past, Present and Future of HLA Typing
Post Your Comments:
(Date:7/23/2008)...Pharmaceuticals (SPI) has filed,an Investigational...l,testing of a proprietary formulation of ebselen ... loss or ototoxicity. The oral capsule,containing ...e lung cancer,and head and neck cancer patients re...e second development program for SPI to enter clin...
(Date:7/23/2008)... Have Greater Concentrations of,Stem Cells, ARLIN.../ -- Fat removed,from the lower abdomen and inner ...lent source of stem cells, with higher stem cell c...s a Brazilian-based study in August,s,Plastic and ...urnal of the,American Society of Plastic Surgeons ...
(Date:7/23/2008)...th Protein Therapeutics that Modulate Al..., Mass., July 23 /- Taligen Therapeut...ate growth plan with the,appointment of Abbie Celn...tablishment of its headquarters in Cambridge, Mass...-founder of the company who remains president., U...
(Date:7/22/2008)...nin Medical, a leading innovator,of physiological ...ntered,the clinical testing phase with its breakth...tion. Today,s most common application for this,tec...al blood oxygenation,in the brain -- cerebral oxim...going clinical study at the,Duke University Medica...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 1Symmetry Medical Delays 10 K Filing to Complete Review 15357 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 3Symmetry Medical Delays 10 K Filing to Complete Review 15357 4Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 1Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 2Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 3Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 1Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 2Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 3Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 1Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 2
...Annual Meeting of the American,Psychiatric Associa...all/ -- In adults with,major depressive disorder, ...) resulted in significant improvement in the prima...ing Scale (MADRS),Total Score. In this six-week, r... at the 160th Annual Meeting of the American,Psych...
...ewswire/ -- Asenapine -- an,investigational drug b...siness unit of Akzo Nobel, for bipolar I disorder ...ffective than placebo,in treating acute manic and ... according to new Phase III results, from a study,...s 2007 Annual,Meeting. , In the three-week study, ...
Other Medicine Technology:Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4
(Date:7/25/2008)...Robert J. Reilly, Joins Aethon Team, PITTSBURGH, ...ethon.com ), the leading developer of mobile robot...ounced that Robert J. Reilly has,joined the compan...cer., Reilly, who was most recently Vice Presiden...ecialty Pharmacy Division, brings more than 30,yea...
(Date:7/25/2008)...an cause immune system changes , , FRIDA...linking gastroesophageal reflux disease (GERD) and...ical Center researchers. , An association betwe..., and since then studies have shown that between 5...xperience GERD symptoms. But the actual link betwe...
(Date:7/25/2008)...mation Association (DIA) and the Food and Drug Adm...iative (CPI) on the Move: Complexities and Challen...cal Path Transporter Workshop (October 2-3; North ... PA (PRWEB) July 25, 2005-- The http://www.diahom...he Food and Drug Administration (FDA) will host th...
(Date:7/24/2008)...wswire/ -- Speaker Nancy Pelosi,released the follo...Lantos,and Henry J. Hyde Global Leadership Against...on Act of 2008. The bill, which passed the Senate ... of 303 to 115 and will now go,the President for h...historic vote to pass landmark legislation to,reau...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
... over have one more reason to raise a toast- a for...s on how you // can pep-up your spirits and reli...Wine Studies at Coventry University, and author of...worthwhile to recall the laws while popping open a...
...ector, K. Sellamuthu, has ordered distribution of ...g places // such as tea stalls, hair cutting sal... as these are the places where large number of pub...was initiated by the Tamilnadu State AIDS Control ...
... delayed to a great extent by taking walks thrice ...ood flow // and leg pain, according to a recent ... be improved through the exercise. As a part of th... of 417 men and women by measuring the distance th...
...Science organization reveal that the detox tablets...The body // has the capacity to take what is esse...he substances that are ingested are not harmful an...he detox industry that includes everything from di...
Other Medicine News:
... is recommended for separations of DNA fragments <...at are easy to handle, and remains flexible even a...f cracking or breaking. Certified PCR agarose, unl...ilar sieving properties, is a standard gelling tem...
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum
Agarose-HR™ High Resolution - Efficiently separates DNA fragments from 50 to 1000 bp. It is useful for sizing PCR fragments, small DNA fragments generated by restriction enzyme digestion, and d
...ning donors on the PK7200 Automated Microplate Sys...d to a gelatin particle for the detection of cytom...f the CMV assay as compared to EIA measures 99.8% ...cle as the carrier provides excellent lot-to-lot c...
Medicine Products: